Newscast – Page 154 – media

AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte

AstraZeneca and Incyte Corporation are pushing forward on the development of immunotherapy combination treatments.
- Source: Cnbc
- 442
- November 2, 2017
AstraZeneca immunotherapy combination
Innovative heart device is safe and effective, study finds

A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery.
- Source: Medicalxpress
- 803
- November 2, 2017
Harpoon Mitral Valve Repair System heart valves
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novartis announced results from the Phase III PARADIGMS study, investigating the safety and efficacy of fingolimod vs. interferon beta-1a, in children and adolescents (ages 10 to <18) with relapsing multiple sclerosis (MS).
- Source: Prnewswire
- 673
- November 1, 2017
Clinical Trial Phase relapsing multiple sclerosis
FDA approves new treatment for adults with mantle cell lymphoma

The U.S. Food and Drug(FDA) Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
- Source: Prnewswire
- 793
- November 1, 2017
Calquence FDA mantle cell lymphoma New Approvals
New Use of A.I. Accurately Detected Cancer 86 Percent of the Time

The quest to better detect cancer has made a potentially huge strides. A study out of Yokohama, Japan, has potentially harnessed artificial intelligence to help detect colorectal cancer even before benign tumors become malignant.
- Source: inverse
- 731
- November 1, 2017
Artificial Intelligence colorectal cancer Market Views
$3.5 Billion Has Been Invested In Digital Health So Far In 2017. Here’s Where The Industry Is Going

Investors in digital health have been busy this year. In the first half of 2017, 188 startups took in $3.5 billion in investments—a record setting amount. It’s not hard to see why. Patients and providers are both looking to digital health tools to get better treatment and improve the relationship dynamic. With all that money flowing into some very intriguing startups, and it’s a good idea to know what the digital health industry holds for us in the coming years.
- Source: huffingtonpost
- 615
- November 1, 2017
digital health doctor Market Views Patients treatment
One Drop Integrates With Fitbit to Deliver Enhanced Diabetes Management Data Insights

One Drop, a leading diabetes care management platform announced they are partnering with Fitbit to help people better manage their Diabetes. By working together, Fitbit and One Drop can help make it easier for people to see how physical activity can impact blood glucose levels and make more informed care management decisions. In addition, One Drop will build an App for Fitbit Ionic, bringing One Drop data to the wrist.
- Source: hitconsultant
- 512
- November 1, 2017
blood glucose levels diabetes Market Views SDK
Samsung Biologics reinforces biologic manufacturing and development partnership with MSD

Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the US and Canada, with the signing of a memorandum of understanding. The relationship has come into force to streamline process development and clinical material production for small biotech start-ups focusing on novel drugs.
- Source: pharmafile
- 435
- November 1, 2017
Merck Samsung Biologics
Scientists pinpoint genetic risk factors for asthma, hay fever and eczema

A major international study has pinpointed more than 100 genetic risk factors that explain why some people suffer from asthma, hay fever and eczema.
- Source: Medicalxpress
- 498
- November 1, 2017
asthma eczema genetic risk hay fever Researches
Merck sales slip, even as Keytruda gains ground

Keytruda (pembrolizumab) was the main bright spot for Merck as it weathered blows from the NotPetya cyber attack, new competition and pricing pressures in hepatitis C.
- Source: 4-traders
- 704
- October 31, 2017
hepatitis inhibitor keytruda Market Views Opdivo

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.